Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy
Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma. Read why I maintain my hold rating for ACLX ...
Targeted Oncology19h
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...